Holocene Advisors LP Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Holocene Advisors LP bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 191,096 shares of the medical research company's stock, valued at approximately $45,284,000. Holocene Advisors LP owned approximately 0.11% of IQVIA at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Versant Capital Management Inc grew its stake in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock valued at $26,000 after buying an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA in the second quarter valued at $27,000. Capital Performance Advisors LLP purchased a new stake in IQVIA during the 3rd quarter worth $27,000. Park Place Capital Corp purchased a new stake in IQVIA during the 3rd quarter worth $28,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in IQVIA during the 2nd quarter worth $29,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of analyst reports. Evercore ISI reduced their price target on IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Truist Financial cut their price objective on IQVIA from $286.00 to $265.00 and set a "buy" rating on the stock in a research note on Monday, November 4th. Redburn Atlantic began coverage on IQVIA in a research note on Monday, October 14th. They set a "buy" rating and a $276.00 price objective on the stock. Morgan Stanley cut their price objective on IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. Finally, StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research report on Thursday, November 28th. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $256.50.

IQVIA Price Performance

NYSE IQV traded down $1.54 on Tuesday, reaching $200.25. 1,171,533 shares of the stock traded hands, compared to its average volume of 1,176,541. The company has a market cap of $36.35 billion, a price-to-earnings ratio of 26.48, a P/E/G ratio of 2.07 and a beta of 1.49. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm's fifty day simple moving average is $217.89 and its 200 day simple moving average is $225.88. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.